Micafungin Viatris

Micafungin, the active ingredient in Micafungin Viatris, is an echinocandin presented as an intravenous formulation for systemic use. It is employed to treat invasive candidiasis, esophageal candidiasis, and to provide prophylaxis against Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product is authorized in the European Union and meets stringent quality standards for export, including compliance with EU GMP guidelines.

Micafungin is an echinocandin antifungal that targets fungal cell wall synthesis, and it is indicated for the following conditions: - Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradication of Candida infection of the esophagus. - Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infections in transplant recipients.

Micafungin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Elevated liver enzymes: transient increase in ALT or AST. - Rash: mild skin erythema. - Infusion‑related reactions: flushing or mild hypotension.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Severe hypersensitivity: anaphylaxis or angioedema. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Renal impairment: acute kidney injury in susceptible patients. - Cardiovascular events: rare arrhythmias or hypotension.

When using Micafungin, consider the following safety measures: - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Concomitant azole antifungals: evaluate for additive hepatotoxicity. - Pregnancy and lactation: weigh potential benefits against unknown risks. - Immunocompromised patients: monitor for breakthrough fungal infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with other medicines; awareness of the interaction level helps guide management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure. - Co‑administration with other echinocandins: increased risk of toxicity; avoid concurrent use.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): monitor liver function for additive effects. - Immunosuppressants (e.g., tacrolimus, cyclosporine): observe drug levels for possible alteration. - Warfarin: check INR more frequently due to potential changes in anticoagulant effect.